{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:46:49Z","timestamp":1792169209754,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00832-x","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:56:52Z","timestamp":1792166212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax-based combinations in high-risk myelodysplastic syndromes: highlights from ASH 2025 & EHA 2026"],"prefix":"10.1186","volume":"15","author":[{"given":"Ines","family":"Zugasti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Cornejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Casta\u00f1o-Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Rodriguez-Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Cortes-Bullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Diaz-Beya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"Suppl 1","key":"832_CR1","doi-asserted-by":"publisher","first-page":"S644","DOI":"10.1016\/S2152-2650(25)02083-X","volume":"25","author":"G Garcia-Manero","year":"2025","unstructured":"Garcia-Manero G, Platzbecker U, Fenaux P, Roboz GJ, Fong CY, Hus M, et al. Primary analysis of the randomized, phase 3 VERONA study of venetoclax with azacitidine versus placebo with azacitidine in patients with treatment-na\u00efve, intermediate and higher-risk myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2025;25(Suppl 1):S644\u20135. https:\/\/doi.org\/10.1016\/S2152-2650(25)02083-X.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"832_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1182\/blood-2025-235","volume":"146","author":"G Garcia-Manero","year":"2025","unstructured":"Garcia-Manero G, Platzbecker U, Fenaux P, Roboz G, Fong CY, Hus M, et al. Subgroup analyses from the randomized, phase 3 VERONA study of venetoclax with azacitidine versus placebo with azacitidine in patients with treatment-na\u00efve, intermediate and higher-risk myelodysplastic syndromes. Blood. 2025;146(Suppl 1):235\u20136. https:\/\/doi.org\/10.1182\/blood-2025-235.","journal-title":"Blood"},{"issue":"Suppl 1","key":"832_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood-2025-239","volume":"146","author":"GSG Murthy","year":"2025","unstructured":"Murthy GSG, Abaza Y, Ball S, Abboud R, Haddadin M, Feld J, et al. Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome: impact of subgroups on clinical outcomes. Blood. 2025;146(Suppl 1):239. https:\/\/doi.org\/10.1182\/blood-2025-239.","journal-title":"Blood"},{"issue":"Suppl 1","key":"832_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2025-237","volume":"146","author":"A Bataller","year":"2025","unstructured":"Bataller A, Bouligny IM, Bazinet A, Montalban-Bravo G, Chien K, Hammond D, et al. Oral decitabine\/cedazuridine in combination with venetoclax in treatment-na\u00efve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: updates of a phase 1\/2 clinical trial. Blood. 2025;146(Suppl 1):237. https:\/\/doi.org\/10.1182\/blood-2025-237.","journal-title":"Blood"},{"issue":"1","key":"832_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41408-025-01245-5","volume":"15","author":"A Bataller","year":"2025","unstructured":"Bataller A, Sasaki K, Urrutia S, Montalban-Bravo G, Bazinet A, Chien K, et al. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood Cancer J. 2025;15(1):50. https:\/\/doi.org\/10.1038\/s41408-025-01245-5.","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"832_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2025-606","volume":"146","author":"JP Bewersdorf","year":"2025","unstructured":"Bewersdorf JP, Kewan T, Lanino L, Wei W, Ali NH, DeZern AE, et al. Outcomes of patients with higher-risk myelodysplastic syndromes treated with hypomethylating agents plus venetoclax: a large analysis from the international consortium for MDS (icMDS) Validate database. Blood. 2025;146(Suppl 1):606. https:\/\/doi.org\/10.1182\/blood-2025-606.","journal-title":"Blood"},{"issue":"6","key":"832_CR7","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3324\/haematol.2025.289268","volume":"111","author":"M Aldapt","year":"2026","unstructured":"Aldapt M, Wang YH, Shah KJ, El Kettani M, Foran J, Kharfan-Dabaja M, et al. Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes. Haematologica. 2026;111(6):2159\u201363. https:\/\/doi.org\/10.3324\/haematol.2025.289268.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"832_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood-2025-238","volume":"146","author":"U Borate","year":"2025","unstructured":"Borate U, Handa S, Dvorak-Kornaus K, Swords R, Lachowiez C, Zhao Q, et al. Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy-related myelodysplastic syndrome. Blood. 2025;146(Suppl 1):238. https:\/\/doi.org\/10.1182\/blood-2025-238.","journal-title":"Blood"},{"issue":"Suppl 1","key":"832_CR9","first-page":"EHA","volume":"10","author":"I Zugasti","year":"2026","unstructured":"Zugasti I, Casta\u00f1o-D\u00edez S, Avenda\u00f1o A, Pomares H, Perez Gonzalez A, Lopez Cadenas F, et al. Venetoclax and azacitidine treatment for high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia as a bridge therapy to transplant: real-life expanded GESMD study. HemaSphere. 2026;10(Suppl 1):EHA\u20132853.","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"832_CR10","first-page":"PS1765","volume":"10","author":"ZS Lyu","year":"2026","unstructured":"Lyu ZS, Sun Y, Mo XD, Lv M, Cheng YF, Xu L, et al. Impact of venetoclax bridging on hematopoietic stem cell transplantation outcomes in advanced myelodysplastic neoplasms. HemaSphere. 2026;10(Suppl 1):PS1765.","journal-title":"HemaSphere"},{"issue":"11","key":"832_CR11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood.2024025464","volume":"145","author":"JS Garcia","year":"2025","unstructured":"Garcia JS, Platzbecker U, Odenike O, Fleming S, Fong CY, Borate U, et al. Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025;145(11):1126\u201335. https:\/\/doi.org\/10.1182\/blood.2024025464.","journal-title":"Blood"},{"issue":"4","key":"832_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324. https:\/\/doi.org\/10.1002\/ajh.27246.","journal-title":"Am J Hematol"},{"issue":"1","key":"832_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40164-025-00652-5","volume":"14","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Lopez-Guerra M, Casta\u00f1o-D\u00edez S, Esteban D, Avenda\u00f1o A, Pomares H, et al. Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study. Exp Hematol Oncol. 2025;14(1):61. https:\/\/doi.org\/10.1186\/s40164-025-00652-5.","journal-title":"Exp Hematol Oncol"},{"issue":"Suppl 1","key":"832_CR14","first-page":"PF660","volume":"10","author":"GSG Murthy","year":"2026","unstructured":"Murthy GSG, Abaza Y, Ball S, Abboud R, Haddadin M, Feld J, et al. Molecular predictors of clinical efficacy with venetoclax and hypomethylating agent in the frontline management of higher-risk myelodysplastic syndrome. HemaSphere. 2026;10(Suppl 1):PF660.","journal-title":"HemaSphere"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00832-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:56:53Z","timestamp":1792166213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00832-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00832-x","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"106"}}